FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892491493> ?p ?o ?g. }

• W2892491493 abstract "Background: The CXCR4/SDF-1α signaling axis is critical for homing of stem cells in the bone marrow and activation of downstream pathways involved in cell proliferation and survival. In an AML model, LY2510924, a peptide antagonist of CXCR4, showed significant anti-leukemia activity. Methods: A phase I study was designed to determine the safety and toxicity profile of combination therapy of LY2510924, idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML. Patients aged 18- 70 years receiving salvage therapy (up to salvage 3) were eligible. LY2510924 is administered daily for 7 days followed by IA starting day 8. Two dose escalation levels (10 and 20 mg) were planned; up to 12 patients were to be enrolled in phase I portion. Results: Eleven patients have been enrolled with a median age of 55 (range, 19-70). Median number of prior therapies was 1 (1-3). Six pts were treated at dose-level ‘0’ (10 mg) and 5 at dose-level ‘1’ (20 mg). Only one patient experiencing a dose limiting toxicity (grade 3 rash and myelosuppression). At the starting dose-level ‘0’, three complete responses (CRs) were observed; at dose-level ‘1’, one achieved CR; the overall response rate was 36% (4 of 11 patients). By flow cytometry, 4 of 9 had ≥ 50% decrease in CXCR4 mean fluorescence intensity, indicating incomplete suppression of CXCR4-receptor occupancy. Conclusions: Combination of LY2510924 with IA is safe in R/R AML pts. Dose-escalation to a 30 mg LY2510924 dose is planned to achieve complete blockade of CXCR4 receptor occupancy, followed by expansion phase at the recommended phase 2 dose-level." @default.
• W2892491493 created "2018-10-05" @default.
• W2892491493 creator A5009603653 @default.
• W2892491493 creator A5013173470 @default.
• W2892491493 creator A5015140142 @default.
• W2892491493 creator A5022647201 @default.
• W2892491493 creator A5024081198 @default.
• W2892491493 creator A5033187606 @default.
• W2892491493 creator A5047351832 @default.
• W2892491493 creator A5049385583 @default.
• W2892491493 creator A5055045706 @default.
• W2892491493 creator A5057357649 @default.
• W2892491493 creator A5057822243 @default.
• W2892491493 creator A5058755419 @default.
• W2892491493 creator A5070065917 @default.
• W2892491493 creator A5071658726 @default.
• W2892491493 creator A5079262854 @default.
• W2892491493 creator A5083793750 @default.
• W2892491493 creator A5084290698 @default.
• W2892491493 creator A5089428686 @default.
• W2892491493 creator A5090435894 @default.
• W2892491493 date "2018-09-24" @default.
• W2892491493 modified "2023-10-17" @default.
• W2892491493 title "Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia" @default.
• W2892491493 cites W1519632334 @default.
• W2892491493 cites W153776372 @default.
• W2892491493 cites W1561964696 @default.
• W2892491493 cites W1569756545 @default.
• W2892491493 cites W174683914 @default.
• W2892491493 cites W1804439365 @default.
• W2892491493 cites W1870350942 @default.
• W2892491493 cites W1881046587 @default.
• W2892491493 cites W1972757472 @default.
• W2892491493 cites W1980917904 @default.
• W2892491493 cites W1996264890 @default.
• W2892491493 cites W2006577811 @default.
• W2892491493 cites W2010655738 @default.
• W2892491493 cites W2013833543 @default.
• W2892491493 cites W2023624246 @default.
• W2892491493 cites W2034573495 @default.
• W2892491493 cites W2038875807 @default.
• W2892491493 cites W2039694224 @default.
• W2892491493 cites W2043046186 @default.
• W2892491493 cites W2049146466 @default.
• W2892491493 cites W2056918364 @default.
• W2892491493 cites W2058554403 @default.
• W2892491493 cites W2070590745 @default.
• W2892491493 cites W2079961239 @default.
• W2892491493 cites W2084139498 @default.
• W2892491493 cites W2086834665 @default.
• W2892491493 cites W2091552147 @default.
• W2892491493 cites W2098290171 @default.
• W2892491493 cites W2101037339 @default.
• W2892491493 cites W2102347658 @default.
• W2892491493 cites W2116018770 @default.
• W2892491493 cites W2120892454 @default.
• W2892491493 cites W2124090816 @default.
• W2892491493 cites W2124514001 @default.
• W2892491493 cites W2128532174 @default.
• W2892491493 cites W2135702406 @default.
• W2892491493 cites W2150833007 @default.
• W2892491493 cites W2153006678 @default.
• W2892491493 cites W2153576284 @default.
• W2892491493 cites W2156323704 @default.
• W2892491493 cites W2159507916 @default.
• W2892491493 cites W2159746057 @default.
• W2892491493 cites W2163065691 @default.
• W2892491493 cites W2331244012 @default.
• W2892491493 cites W2401306704 @default.
• W2892491493 cites W2419014270 @default.
• W2892491493 cites W2466569700 @default.
• W2892491493 cites W2472104278 @default.
• W2892491493 cites W2472847191 @default.
• W2892491493 cites W2473008633 @default.
• W2892491493 cites W2561193801 @default.
• W2892491493 cites W2592251814 @default.
• W2892491493 cites W2592358054 @default.
• W2892491493 cites W2593366005 @default.
• W2892491493 cites W2598957611 @default.
• W2892491493 cites W2613582579 @default.
• W2892491493 cites W2738123701 @default.
• W2892491493 cites W2747505453 @default.
• W2892491493 cites W2764273516 @default.
• W2892491493 cites W2782511872 @default.
• W2892491493 cites W2806158832 @default.
• W2892491493 cites W3112284273 @default.
• W2892491493 cites W4256176606 @default.
• W2892491493 cites W4376595466 @default.
• W2892491493 doi "https://doi.org/10.3389/fonc.2018.00369" @default.
• W2892491493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6167965" @default.
• W2892491493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30319961" @default.
• W2892491493 hasPublicationYear "2018" @default.
• W2892491493 type Work @default.
• W2892491493 sameAs 2892491493 @default.
• W2892491493 citedByCount "24" @default.
• W2892491493 countsByYear W28924914932019 @default.
• W2892491493 countsByYear W28924914932020 @default.
• W2892491493 countsByYear W28924914932021 @default.
• W2892491493 countsByYear W28924914932022 @default.
• W2892491493 countsByYear W28924914932023 @default.

• next